{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T06:16:10Z","timestamp":1783145770585,"version":"3.54.6"},"reference-count":28,"publisher":"Kurume Medical Journal","issue":"1.2.3.4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kurume Med. J."],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.2739\/kurumemedj.ms721234004","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T22:08:19Z","timestamp":1769638099000},"page":"29-37","source":"Crossref","is-referenced-by-count":0,"title":["Circulating Thrombospondin-2 Levels Reflect Hepatic Fibrosis Severity and Renal Dysfunction in a General Population: Uku Study"],"prefix":"10.2739","volume":"72","author":[{"given":"SACHIKO","family":"KYOGOKU","sequence":"first","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HISASHI","family":"ADACHI","sequence":"additional","affiliation":[{"name":"Keikokai Hara Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MIKA","family":"ENOMOTO","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AKO","family":"FUKAMI","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YUME","family":"NOHARA","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NAGISA","family":"MORIKAWA","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HIROMI","family":"SATO","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HARUMI","family":"TAKUBO","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MAYO","family":"SHIMOYAMA","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YOSHIHIRO","family":"FUKUMOTO","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Department of Internal Medicine, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1445","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Mustonen E, Ruskoaho H, and Rys\u00e4 J. Thrombospondins, potential drug targets for cardiovascular diseases. Basic Clin Pharmacol Toxicol 2013; 112:4-12.","DOI":"10.1111\/bcpt.12026"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Agah A, Kyriakides TR, Lawler J, and Bornstein P. The lack of thrombospondin-1 (TSP1) dictates the course of wound healing in double-TSP1\/TSP2-null mice. Am J Pathol 2002; 161:831-839.","DOI":"10.1016\/S0002-9440(10)64243-5"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Min-DeBartolo J, Schlerman F, Akare S, Wang J, McMahon J et al. Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH). PLoS One 2019; 14:e0226854.","DOI":"10.1371\/journal.pone.0226854"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Bai J, Xia M, Xue Y, Ma F, Cui A et al. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans. EBioMedicine 2020; 57:102849.","DOI":"10.1016\/j.ebiom.2020.102849"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Lou Y, Tian GY, Song Y, Liu YL, Chen YD et al. Characterization of transcriptional modules related to fibrosing-NAFLD progression. Sci Rep 2017; 7:4748.","DOI":"10.1038\/s41598-017-05044-2"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Kimura T, Tanaka N, Fujimori N, Yamazaki T, Katsuyama T et al. Serum thrombospondin 2 is a novel predictor for the severity in the patients with NAFLD. Liver Int 2021; 41:505-514.","DOI":"10.1111\/liv.14776"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Lee CH, Seto WK, Lui DT, Fong CH, Wan HY et al. Circulating thrombospondin-2 as a novel fibrosis biomarker of nonalcoholic fatty liver disease in type 2 diabetes. Diabetes Care 2021; 44:2089-2097.","DOI":"10.2337\/dc21-0131"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Iwadare T, Kimura T, Tanaka N, Yamazaki T, Wakabayashi SI et al. Circulating thrombospondin 2 levels reflect fibrosis severity and disease activity in HCV-infected patients. Sci Rep 2022; 12:18900.","DOI":"10.1038\/s41598-022-23357-9"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Morikawa N, Adachi H, Enomoto M, Fukami A, Kumagai E et al. Thrombospondin-2 as a potential risk factor in a general population. Int Heart J 2019; 60:310-317.","DOI":"10.1536\/ihj.18-246"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Lin Z, Zhang D, Zhang X, Guo W, Wang W et al. Extracellular status of thrombospondin-2 in type 2 diabetes mellitus and utility as a biomarker in the determination of early diabetic kidney disease. BMC Nephrol 2023; 24:154.","DOI":"10.1186\/s12882-023-03216-z"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Adachi H, Kakuma T, Enomoto M, Fukami A, Nakamura S et al. Correlation between estimated plasma remnant-like particle cholesterol and vegetable fat intake in Uku town, Japan. Environ Health Prev Med 2021; 26:82.","DOI":"10.1186\/s12199-021-01005-4"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Tahara N, Tahara A, Maeda-Ogata S, Yoshimura H, Bekki M et al. Increased urinary levels of pentosidine measured by a newly developed enzyme-linked immunosorbent assay are independently correlated with fracture after fall. Rejuvenation Res 2021; 24:449-455.","DOI":"10.1089\/rej.2021.0066"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53:982-992.","DOI":"10.1053\/j.ajkd.2008.12.034"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ et al. Nash Clinical Research Network. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7:1104-1112.","DOI":"10.1016\/j.cgh.2009.05.033"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Sumida Y, Yoneda M, Hyogo H, Itoh Y, Ono M et al. Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol. 2012; 12:2.","DOI":"10.1186\/1471-230X-12-2"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kobayashi S, Murakami K, Sasaki S, Okubo H, Hirota N et al. Comparison of relative validity of food group intakes estimated by comprehensive and brief-type self-administered diet history questionnaires against 16 d dietary records in Japanese adults. Public Health Nutr 2011; 14:1200-1211.","DOI":"10.1017\/S1368980011000504"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kobayashi S, Honda S, Murakami K, Sasaki S, Okubo H et al. Both comprehensive and brief self-administered diet history questionnaires satisfactorily rank nutrient intakes in Japanese adults. J Epidemiol 2012; 22:151-159.","DOI":"10.2188\/jea.JE20110075"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Zhang K, Li M, Yin L, Fu G, and Liu Z. Role of thrombospondin 1 and thrombospondin 2 in cardiovascular diseases (Review). Int J Mol Med 2020; 45:1275-1293.","DOI":"10.3892\/ijmm.2020.4507"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Hanatani S, Izumiya Y, Takashio S, Kimura Y, Araki S et al. Circulating thrombospondin-2 reflects disease severity and predicts outcome of heart failure with reduced ejection fraction. Circ J 2014; 78:903-910.","DOI":"10.1253\/circj.CJ-13-1221"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Lee CH, Wu MZ, Lui D, Fong C, Ren QW et al. Prospective associations of circulating thrombospondin-2 level with heart failure hospitalization, left ventricular remodeling and diastolic function in type 2 diabetes. Cardiovasc Diabetol 2022; 21:231.","DOI":"10.1186\/s12933-022-01646-x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Girerd N, Levy D, Duarte K, Ferreira JP, Ballantyne C et al. Protein biomarkers of new-onset heart failure: Insights from the heart omics and ageing cohort, the Atherosclerosis Risk in Communities Study, and the Framingham Heart Study. Circ Heart Fail 2023; 16:e009694.","DOI":"10.1161\/CIRCHEARTFAILURE.122.009694"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Lee CH, Lui DT, Cheung CY, Fong CH, Yuen MM et al. Circulating thrombospondin-2 level for identifying individuals with rapidly declining kidney function trajectory in type 2 diabetes: a prospective study of the Hong Kong West Diabetes Registry. Nephrol Dial Transplant. 2023 (in press).","DOI":"10.1093\/ndt\/gfad034"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Navarro-Sobrino M, Rosell A, Hern\u00e1ndez-Guillamon M, Penalba A, Boada C et al. A large screening of angiogenesis biomarkers and their association with neurological outcome after ischemic stroke. Atherosclerosis 2011; 216:205-211.","DOI":"10.1016\/j.atherosclerosis.2011.01.030"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Kajihara I, Jinnin M, Yamane K, Makino T, Honda N et al. Increased accumulation of extracellular thrombospondin-2 due to low degradation activity stimulates type \u2160 collagen expression in scleroderma fibroblasts. Am J Pathol 2012; 180:703-714.","DOI":"10.1016\/j.ajpath.2011.10.030"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Daniel C, Wagner A, Hohenstein B, and Hugo C. Thrombospondin-2 therapy ameliorates experimental glomerulonephritis via inhibition of cell proliferation, inflammation, and TGF-beta activation. Am J Physiol Renal Physiol 2009; 297:F1299-F1309.","DOI":"10.1152\/ajprenal.00254.2009"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Hugo C and Daniel C. Thrombospondin in renal disease. Nephron Exp Nephrol 2009; 111:e61-e66.","DOI":"10.1159\/000198235"},{"key":"27","doi-asserted-by":"publisher","unstructured":"27. Border WA, Noble NA, Yamamoto T, Harper JR, Yamaguchi Y et al. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 1992; 360:361-364.","DOI":"10.1038\/360361a0"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Tamaki K and Okuda S. Role of TGF-beta in the progression of renal fibrosis. Contrib Nephrol 2003; 139:44-65.","DOI":"10.1159\/000071736"}],"container-title":["The Kurume Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/kurumemedj\/72\/1.2.3.4\/72_MS721234004\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T05:21:32Z","timestamp":1783142492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/kurumemedj\/72\/1.2.3.4\/72_MS721234004\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":28,"journal-issue":{"issue":"1.2.3.4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2739\/kurumemedj.ms721234004","relation":{},"ISSN":["0023-5679","1881-2090"],"issn-type":[{"value":"0023-5679","type":"print"},{"value":"1881-2090","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,31]]},"article-number":"MS721234004"}}